Form 4: Perceptive Advisors Divests LYRA Shares Under 10b5-1 Plan

Perceptive Advisors and related entities reported the sale of Lyra Therapeutics common stock in mid-November 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd, Perceptive LS (A), LLC, and Joseph Edelman, collectively identified as a Director and 10% Owner of Lyra Therapeutics, Inc. (LYRA), reported sales of common stock.
• A total of 45,875 shares of common stock were disposed of across multiple transactions between November 11, 2025, and November 13, 2025.
• On November 11, 2025, 4,783 shares were sold at a weighted average price of $4.3146 (ranging from $4.25 to $4.61) and 537 shares were sold at the same weighted average price.
• On November 12, 2025, 7,862 shares were sold at a weighted average price of $4.0594 (ranging from $3.90 to $4.27) and 883 shares were sold at the same weighted average price.
• On November 13, 2025, 28,597 shares were sold at a weighted average price of $3.9001 (ranging from $3.90 to $3.91) and 3,213 shares were sold at the same weighted average price.
• Following these transactions, the Master Fund holds 124,859 shares and Perceptive LS holds 14,026 shares, totaling 138,885 shares beneficially owned indirectly.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sales represent a reduction in a significant holder's stake, the execution under a Rule 10b5-1 plan indicates pre-planned divestment, reducing the implication of immediate negative sentiment from the insider.

Negatives

• A significant 10% owner and director, Perceptive Advisors and its affiliates, reduced their stake in Lyra Therapeutics by selling 45,875 shares of common stock.

Risks

• The reduction in ownership by a major institutional investor and director could be perceived by the market as a signal of reduced confidence in the company's future prospects, potentially leading to negative share price pressure.
• While executed under a 10b5-1 plan, the divestment still represents a decrease in the alignment of interests between this significant shareholder and other common shareholders.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's operational or financial performance. It solely reports past insider transactions.

Industry Context

This filing reports an insider transaction, which is a routine disclosure for publicly traded companies. The sale of shares by a significant institutional investor and director, even under a 10b5-1 plan, is a data point for market participants to consider in their assessment of the company within the broader biotechnology industry.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by a 10% owner and director as a potential lack of conviction, which could influence their investment decisions.
• The transparency provided by the Form 4 filing allows all stakeholders to monitor insider activity and assess potential implications for the company's stock.

Key Dates

Recommendation

The reported sales by Perceptive Advisors and its affiliates, a 10% owner and director, are significant. However, the transactions were conducted under a Rule 10b5-1 plan, which suggests these were pre-scheduled divestments rather than a reaction to new, adverse material information. While a reduction in insider ownership can be a negative signal, the 10b5-1 plan mitigates the immediate concern. Investors should 'hold' and monitor future filings and company performance, as this specific transaction does not necessarily indicate a fundamental shift in the company's prospects but rather a planned portfolio adjustment by a major investor.

Keywords

Lyra Therapeutics, LYRA, Perceptive Advisors, Insider Selling, Form 4, Beneficial Ownership, 10b5-1 Plan, Equity Sales, Biotechnology